Shire PLC (LON:SHP) Rating
Exane BNP Paribas currently has a GBX 5700.00 price target on the 22.03B GBP market cap company or 48.28% upside potential. In an analyst note issued to clients on Monday morning, Shire PLC (LON:SHP) stock had its “Outperform” Rating maintained by expert analysts at Exane BNP Paribas.
Out of 9 analysts covering Shire PLC (LON:SHP), 13 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. GBX 81.37 is the highest target while GBX 71.37 is the lowest. The GBX 76.53 average target is 35.82% above today’s (GBX 3746) stock price. Shire PLC was the topic in 127 analyst reports since July 24, 2015 according to StockzIntelligence Inc. AlphaValue maintained the stock on March 10 with “Buy” rating. Berenberg maintained it with “Buy” rating and GBX 5400 target price in a February 17 report. Bernstein maintained the shares of SHP in a report on March 7 with “Outperform” rating. J.P. Morgan maintained the firm’s rating on February 16. J.P. Morgan has “Overweight” rating and GBX 5300 price target. Finally, UBS maintained the stock with “Buy” rating in a February 24 report.
About 229,605 shares traded hands. Shire PLC (LON:SHP) has declined 28.45% since August 13, 2015 and is downtrending. It has underperformed by 25.50% the S&P500.
Shire plc is a biopharmaceutical company. The company has a market cap of 22.03 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 23.89 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.